Stock Research for RGEN

RGEN
Current Price

$32.7600


Latest Update: 2018-02-16 16:00:00

High
$ 32.7800
Low
$ 32.7100
Close
$ 32.7500
Volume
13067
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

RGEN Stock Chart & Research Data

The RGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RGEN Due diligence Resources & Stock Charts

The RGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RGEN Detailed Price Forecast - CNN Money CNN View RGEN Detailed Summary - Google Finance
Yahoo View RGEN Detailed Summary - Yahoo! Finance Zacks View RGEN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View RGEN Trends & Analysis - Trade-Ideas Barrons View RGEN Major Holders - Barrons
NASDAQ View RGEN Call Transcripts - NASDAQ Seeking View RGEN Breaking News & Analysis - Seeking Alpha
Spotlight View RGEN Annual Report - CompanySpotlight.com OTC Report View RGEN OTC Short Report - OTCShortReport.com
TradeKing View RGEN Fundamentals - TradeKing Charts View RGEN SEC Filings - Bar Chart
WSJ View Historical Prices for RGEN - The WSJ Morningstar View Performance/Total Return for RGEN - Morningstar
MarketWatch View the Analyst Estimates for RGEN - MarketWatch CNBC View the Earnings History for RGEN - CNBC
StockMarketWatch View the RGEN Earnings - StockMarketWatch MacroAxis View RGEN Buy or Sell Recommendations - MacroAxis
Bullish View the RGEN Bullish Patterns - American Bulls Short Pains View RGEN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View RGEN Stock Mentions - StockTwits PennyStocks View RGEN Stock Mentions - PennyStockTweets
Twitter View RGEN Stock Mentions - Twitter Invest Hub View RGEN Investment Forum News - Investor Hub
Yahoo View RGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View RGEN Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for RGEN - SECform4.com Insider Cow View Insider Transactions for RGEN - Insider Cow
CNBC View RGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RGEN - OTC Markets
Yahoo View Insider Transactions for RGEN - Yahoo! Finance NASDAQ View Institutional Holdings for RGEN - NASDAQ


Stock Charts

FinViz View RGEN Stock Insight & Charts - FinViz.com StockCharts View RGEN Investment Charts - StockCharts.com
BarChart View RGEN Stock Overview & Charts - BarChart Trading View View RGEN User Generated Charts - Trading View


Latest Financial News for RGEN

Repligen to Report Fourth Quarter and Full Year 2017 Financial Results
Posted on Friday February 16, 2018

WALTHAM, Mass., Feb. 16, 2018-- Repligen Corporation today announced that the Company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018. The Company will issue ...


See what the IHS Markit Score report has to say about Repligen Corp.
Posted on Friday February 02, 2018

Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.


Report: Developing Opportunities within Repligen, Avid Technology, Reata Pharmaceuticals, Stellus Capital Investment, American Financial Group, and Actuant — Future Expectations, Projections Moving into 2018
Posted on Wednesday January 17, 2018

NEW YORK, Jan. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Repligen ...


Repligen To Present at 36th Annual J.P. Morgan Healthcare Conference
Posted on Friday December 29, 2017

WALTHAM, Mass., Dec. 29, 2017-- Repligen Corporation, a leading bioprocessing-focused company delivering technology innovation to improve biologic drug manufacturing flexibility and efficiency, today announced ...


Repligen Corporation and Spectrum, Inc. to Join Forces
GlobeNewswire (press release) - Jun 23, 2017
WALTHAM, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive merger agreement with privately-held ...
Repligen agrees to buy Spectrum for $359 million - The Boston Globe
Repligen to merge with Spectrum in $359M deal - Seeking Alpha

Repligen to Report Fourth Quarter and Full Year 2017 Financial Results
GlobeNewswire (press release) - Feb 16, 2018
WALTHAM, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018.

Will Repligen Corporation (NASDAQ:RGEN) Continue To Underperform Its Industry?
Simply Wall St - Feb 13, 2018
Repligen Corporation's (NASDAQ:RGEN) most recent return on equity was a substandard 5.70% relative to its industry performance of 16.06% over the past year.

Repligen Corporation (RGEN) Plunges 5.33% on February 08
Equities.com - Feb 8, 2018
Repligen Corporation (RGEN) had a rough trading day for Thursday February 08 as shares tumbled 5.33%, or a loss of $-1.74 per share, to close at $30.92.
EPS for Repligen Corporation (RGEN) Expected At $0.12 - BZ Weekly

Enter a stock symbol to view the stock details.